Cervical cancers after human papillomavirus vaccination

Obstetrics and Gynecology

Volumn 113, Issue 2 PART 2, 2009, Pages 550-552

  Beller, Uziel ^a   Abu Rustum, Nadeem R ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; TOPOTECAN; WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18;

ADULT; ARTICLE; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CASE REPORT; CLEAR CELL CARCINOMA; CLINICAL FEATURE; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN TISSUE; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PAPANICOLAOU TEST; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA; UTERINE CERVIX DYSPLASIA; VACCINATION; VIRUS INFECTION; ADENOCARCINOMA; ADOLESCENT; ALPHAPAPILLOMAVIRUS; PATHOLOGY; UTERINE CERVIX TUMOR; VIROLOGY;

ADENOCARCINOMA, CLEAR CELL; ADOLESCENT; ADULT; ALPHAPAPILLOMAVIRUS; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 60549084915     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e318191a54a     Document Type: Article

References (9)

1. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.
2. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
3. Clifford G, Franceschi S, Diaz M, Muñoz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006;24:S26-34.
4. Agosti JM, Goldie SJ. Introducing HPV vaccine in developing countrieskey challenges and issues. N Engl J Med 2007;356: 1908-10.
5. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 viruslike-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007;369:1693-702.
6. Smith-McCune KK. Human papillomavirus vaccine efficacy: aligning expectations with reality [editorial]. Gynecol Oncol 2008;111:1-2.
7. Iannelli M, Martcheva M, Li XZ. Strain replacement in an epidemic model with super-infection and perfect vaccination. Math Biosci 2005;195:23-46.
8. Abu-Rustum NR, Neubauer N, Sonoda Y, Park KJ, Gemignani M, Alektiar KM, et al. Surgical and pathologic outcomes of fertility-sparing radical abdominal trachelectomy for FIGO stage IB1 cervical cancer. Gynecol Oncol 2008;111: 261-4.
9. Pirog EC, Kleter B, Olgac S, Bobkiewicz P, Lindeman J, Quint WG, et al. Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. Am J Pathol 2000;157:1055-62.